FDA grants breakthrough designation for new AI model to detect cardiac amyloidosis in ECG results

Related Articles
Anumana Named to Fast Company’s 2024 Next Big Things in Tech Awards
Award recognizes Anumana’s innovative AI-driven cardiovascular disease detection technologyNovember 19, 2024
Mayo-developed AI detects heart condition from Apple Watch ECGs
Modern Healthcare: An artificial-intelligence algorithm developed at Mayo Clinic could identify left ventricular dysfunction—or a weak heart pump—in most patients based on Apple Watch data, researchers shared at a conference…April 30, 2022
New Project Trains AI on a Hard-to-Diagnose Cardiac Issue
Health Leaders: A start-up from the Mayo Clinic orbit is partnering with Pfizer to develop an AI-enhanced ECG that can detect cardiac amyloidosis, a progressive disease that's difficult to diagnose…December 16, 2022
Anumana’s AI tool for pulmonary hypertension gets FDA breakthrough status
Medical Device Network: Anumana has received US Food and Drug Administration (FDA) Breakthrough Device Designation for its artificial intelligence (AI)-enhanced, electrocardiogram (ECG)-based Pulmonary Hypertension (PH) Early Detection Algorithm. The accurate,…May 24, 2022


